<ul>
<li>傑龍公司：FDA 批准推動股價飆升</li>
</ul>
<p>傑龍公司（NASDAQ:GERN - 免費報告）- Wedbush 在 2023 年 8 月 6 日向投資者發佈的研究報告中，發佈了對傑龍 2026 年第一季度每股收益（EPS）的預期。Wedbush 分析師 R. Driscoll 預計該生物製藥公司本季度每股收益為（$0.02）。傑龍當前全年的共識預期為每股收益（$0.25）。Wedbush 還對傑龍 2026 年第二季度的每股收益預期為$0.00，2026 年第三季度的每股收益預期為$0.02，2026 年第四季度的每股收益預期為$0.04，2026 財年的每股收益預期為$0.04，以及 2027 財年的每股收益預期為$0.37。</p>
<p>傑龍（NASDAQ:GERN - 獲取免費報告）在 2023 年 8 月 6 日發佈了季度財報。該生物製藥公司報告本季度每股收益為（$0.02），超出分析師共識預期的（$0.03）$0.01。該公司本季度的收入為 4904 萬美元，而分析師的預期為 4730 萬美元。傑龍的股本回報率為負 30.79%，淨利潤率為負 53.52%。該公司的季度收入同比增長 5455.6%。在去年同期，該公司每股收益為（$0.10）。</p>
<ul>
<li>傑龍股票在伊美替斯獲得 FDA 小組批准後翻倍</li>
</ul>
<p>GERN 曾是幾份其他研究報告的主題。高盛集團在 2023 年 7 月 10 日發佈的研究報告中對傑龍進行了覆蓋，給予 “賣出” 評級，並設定目標價為$1.00。加拿大豐業銀行在 2023 年 5 月 8 日的研究報告中將傑龍的評級從 “行業跑贏” 下調至 “行業表現”，並將其目標價從$4.00 下調至$1.50。一位股票研究分析師給予該股票 “賣出” 評級，三位給予 “持有” 評級，五位給予 “買入” 評級，一位給予 “強烈買入” 評級。根據 MarketBeat.com 的數據，傑龍的共識評級為 “適度買入”，共識目標價為$4.61。</p>
<p><strong>查看我們最新的傑龍股票報告</strong></p>
<h2>傑龍股票表現</h2>
<p>在週五的午盤交易中，GERN 下跌$0.02，報$1.29。該公司的交易量為 2,104,608 股，而其平均交易量為 12,713,486 股。該公司的速動比率為 6.97，流動比率為 7.87，債務與股本比率為 0.44。該公司的 50 日移動平均線為$1.39，200 日移動平均線為$1.68。該公司的市值為 8.1844 億美元，市盈率為-9.88，貝塔值為 0.73。傑龍的 1 年最低價為$1.09，1 年最高價為$4.84。</p>
<h2>機構投資者對傑龍的看法</h2>
<p>機構投資者最近調整了對該股票的持有。Integrated Wealth Concepts LLC 在第四季度購買了傑龍的新股份，價值約$36,000。GF Fund Management CO. LTD.在第四季度購買了傑龍的新股份，價值$45,000。111 Capital 在第四季度購買了傑龍的新股份，價值$52,000。Fifth Lane Capital LP 在第四季度購買了傑龍的新股份，價值$53,000。最後，Harvest Investment Services LLC 在第四季度購買了傑龍的新股份，價值$61,000。73.71% 的股票由機構投資者持有。</p>
<h2>關於傑龍</h2>
<p>（獲取免費報告）</p>
<p>傑龍公司是一家處於後期臨牀階段的生物製藥公司，專注於針對髓系血液惡性腫瘤的治療藥物的開發和商業化。它開發的伊美替斯是一種端粒酶抑制劑，目前處於第三階段臨牀試驗中，能夠抑制髓系血液惡性腫瘤中惡性幹細胞和祖細胞的失控增殖，用於治療低風險或中等風險的骨髓增生異常綜合症以及中等風險或高風險的骨髓纖維化。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比傑龍更好</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>為什麼 Axon 的 16% 飆升預示着公共安全技術的新紀元</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>DraftKings 發佈創紀錄季度，瞄準盈利</li>
<li>內部人士賣出解釋：它能否影響你的投資選擇？</li>
<li>亞馬遜在 IonQ 中獲得股權投資——有任何上升潛力嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在傑龍嗎？</h2>
<p>在你考慮傑龍之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而傑龍並不在名單上。</p>
<p>雖然傑龍目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>查看這五隻股票</p>

傑龍公司

<p>Wedbush 發佈了對傑龍公司（NASDAQ: GERN）2026 年第一季度的收益預估，預計每股收益為（$0.02）。全年共識為每股（$0.25）。傑龍在上個季度報告的收入為 4904 萬美元，超出預期。該股票獲得了分析師的混合評級，綜合評級為 “適度買入”，目標價格為 4.61 美元。傑龍專注於血液惡性腫瘤的治療，其關鍵產品 imetelstat 正在進行第三階段臨牀試驗</p>

<ul>
<li>Geron Corporation: FDA Approval Fuels Stock Price Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>傑龍公司：FDA 批准推動股價飆升</li>
</ul>
</div><p>Geron Corporation (NASDAQ:GERN - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Geron in a research note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will earn ($0.02) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at $0.37 EPS.</p>
<div class="lb-trans"><p>傑龍公司（NASDAQ:GERN - 免費報告）- Wedbush 在 2023 年 8 月 6 日向投資者發佈的研究報告中，發佈了對傑龍 2026 年第一季度每股收益（EPS）的預期。Wedbush 分析師 R. Driscoll 預計該生物製藥公司本季度每股收益為（$0.02）。傑龍當前全年的共識預期為每股收益（$0.25）。Wedbush 還對傑龍 2026 年第二季度的每股收益預期為$0.00，2026 年第三季度的每股收益預期為$0.02，2026 年第四季度的每股收益預期為$0.04，2026 財年的每股收益預期為$0.04，以及 2027 財年的每股收益預期為$0.37。</p>
</div><p>Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. Geron had a negative return on equity of 30.79% and a negative net margin of 53.52%. The business's quarterly revenue was up 5455.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share.</p>
<div class="lb-trans"><p>傑龍（NASDAQ:GERN - 獲取免費報告）在 2023 年 8 月 6 日發佈了季度財報。該生物製藥公司報告本季度每股收益為（$0.02），超出分析師共識預期的（$0.03）$0.01。該公司本季度的收入為 4904 萬美元，而分析師的預期為 4730 萬美元。傑龍的股本回報率為負 30.79%，淨利潤率為負 53.52%。該公司的季度收入同比增長 5455.6%。在去年同期，該公司每股收益為（$0.10）。</p>
</div><ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><ul>
<li>傑龍股票在伊美替斯獲得 FDA 小組批准後翻倍</li>
</ul>
</div><p>GERN has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They set a &#34;sell&#34; rating and a $1.00 target price for the company. Scotiabank cut Geron from a &#34;sector outperform&#34; rating to a &#34;sector perform&#34; rating and cut their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $4.61.</p>
<div class="lb-trans"><p>GERN 曾是幾份其他研究報告的主題。高盛集團在 2023 年 7 月 10 日發佈的研究報告中對傑龍進行了覆蓋，給予 “賣出” 評級，並設定目標價為$1.00。加拿大豐業銀行在 2023 年 5 月 8 日的研究報告中將傑龍的評級從 “行業跑贏” 下調至 “行業表現”，並將其目標價從$4.00 下調至$1.50。一位股票研究分析師給予該股票 “賣出” 評級，三位給予 “持有” 評級，五位給予 “買入” 評級，一位給予 “強烈買入” 評級。根據 MarketBeat.com 的數據，傑龍的共識評級為 “適度買入”，共識目標價為$4.61。</p>
</div><p><strong>View Our Latest Stock Report on GERN</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的傑龍股票報告</strong></p>
</div><h2>Geron Stock Performance</h2>
<div class="lb-trans"><h2>傑龍股票表現</h2>
</div><p>GERN traded down $0.02 during midday trading on Friday, reaching $1.29. The company had a trading volume of 2,104,608 shares, compared to its average volume of 12,713,486. The company has a quick ratio of 6.97, a current ratio of 7.87 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.68. The company has a market cap of $818.44 million, a P/E ratio of -9.88 and a beta of 0.73. Geron has a 1 year low of $1.09 and a 1 year high of $4.84.</p>
<div class="lb-trans"><p>在週五的午盤交易中，GERN 下跌$0.02，報$1.29。該公司的交易量為 2,104,608 股，而其平均交易量為 12,713,486 股。該公司的速動比率為 6.97，流動比率為 7.87，債務與股本比率為 0.44。該公司的 50 日移動平均線為$1.39，200 日移動平均線為$1.68。該公司的市值為 8.1844 億美元，市盈率為-9.88，貝塔值為 0.73。傑龍的 1 年最低價為$1.09，1 年最高價為$4.84。</p>
</div><h2>Institutional Investors Weigh In On Geron</h2>
<div class="lb-trans"><h2>機構投資者對傑龍的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the fourth quarter worth $45,000. 111 Capital bought a new stake in shares of Geron during the fourth quarter worth $52,000. Fifth Lane Capital LP bought a new stake in shares of Geron during the fourth quarter worth $53,000. Finally, Harvest Investment Services LLC bought a new stake in shares of Geron during the fourth quarter worth $61,000. 73.71% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該股票的持有。Integrated Wealth Concepts LLC 在第四季度購買了傑龍的新股份，價值約$36,000。GF Fund Management CO. LTD.在第四季度購買了傑龍的新股份，價值$45,000。111 Capital 在第四季度購買了傑龍的新股份，價值$52,000。Fifth Lane Capital LP 在第四季度購買了傑龍的新股份，價值$53,000。最後，Harvest Investment Services LLC 在第四季度購買了傑龍的新股份，價值$61,000。73.71% 的股票由機構投資者持有。</p>
</div><h2>About Geron</h2>
<div class="lb-trans"><h2>關於傑龍</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.</p>
<div class="lb-trans"><p>傑龍公司是一家處於後期臨牀階段的生物製藥公司，專注於針對髓系血液惡性腫瘤的治療藥物的開發和商業化。它開發的伊美替斯是一種端粒酶抑制劑，目前處於第三階段臨牀試驗中，能夠抑制髓系血液惡性腫瘤中惡性幹細胞和祖細胞的失控增殖，用於治療低風險或中等風險的骨髓增生異常綜合症以及中等風險或高風險的骨髓纖維化。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Geron</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比傑龍更好</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>為什麼 Axon 的 16% 飆升預示着公共安全技術的新紀元</li>
<li>高分紅 REIT：它們是理想的多元化方式嗎？</li>
<li>DraftKings 發佈創紀錄季度，瞄準盈利</li>
<li>內部人士賣出解釋：它能否影響你的投資選擇？</li>
<li>亞馬遜在 IonQ 中獲得股權投資——有任何上升潛力嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=GERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Geron Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在傑龍嗎？</h2>
</div><p>Before you consider Geron, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮傑龍之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而傑龍並不在名單上。</p>
</div><p>While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然傑龍目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Wedbush 對傑龍公司第一季度收益的預測是什麼？